HOME >> MEDICINE >> NEWS
Targeted therapy shows significant benefits over standard treatment for advanced kidney cancer

ATLANTA According to a new study, the drug sunitinib malate (Sutent) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

"This drug has shown more activity as a single agent against advanced kidney cancer than any other drug I've studied in the past 15 years," said the study's lead author Robert J. Motzer, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). "I continue to be encouraged by its effectiveness in treating patients with this aggressive disease," said Dr. Motzer, who is a leader in the treatment of kidney cancer and conducted the earliest clinical trials on sunitinib (initially referred to as SU11248).

Interferon-alpha (IFN-) is one of the standard treatments for advanced kidney cancer, however only about 15 percent of patients respond to this immunotherapy. Sunitinib targets receptors on kidney cancer cells that may play a role in tumor growth and the development of blood vessels that feed a tumor. Previous clinical trials, also led by Dr. Motzer, showed that sunitinib caused some renal cell cancers to shrink, but this study is the first to demonstrate its effectiveness as a first-line therapy compared with standard cytokine therapy with IFN-.

The current randomized trial included 750 patients over the age of 60, half of whom were treated with a six-week cycle of sunitinib and half of whom were treated with a six-week cycle of the current treatment standard, IFN-. The primary endpoint of the trial was a comparison of progression-free survival between sunitinib and IFN- as assessed by independent third-party review. The median progression-free survival for treatment with sunitinib was 11 months, compared with 5 months following treatment with IFN-. This outcome was statistical
'"/>

Contact: Maria Connizzo
mediastaff@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
4-Jun-2006


Page: 1 2

Related medicine news :

1. Targeted, oral agent Enzastaurin shows favorable results
2. Targeted initiatives can encourage people to walk more
3. Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
4. Targeted cancer drugs may work by disrupting balance of cellular signals
5. Targeted melanoma education of high risk groups improves screening
6. Targeted lymph node examination improves staging of colon cancer
7. Targeted cancer drug combined with low-dose chemotherapy shrinks tumors, slows ovarian cancer
8. Chemotherapy with bevacizumab increases risk of blood clots in arteries
9. Nonsmall cell lung cancer -- chemotherapy before surgery appears better than surgery alone
10. Stroke in nonvascular atrial fibrillation -- anti-coagulants better than anti-platelet therapy
11. Hormone therapy offers new hope for ovarian cancer patients

Post Your Comments:
(Date:5/27/2015)... With the launch of the Centers for Medicare ... (NMM) tool, monitoring provider-network adequacy will take a technological ... Services, Inc.’s (AIS) Medicare Advantage News (MAN) offers in-depth ... analysis from industry experts on why CMS is moving ... NMM were announced at CMS’s recently held annual spring ...
(Date:5/27/2015)... 2015 The new http://www.carsonenergy.com ... investors should consider oil and gas investing, the substantial ... are drilled, industry news, IRA investing, definitions and acronyms, ... of knowledge and experience is now in one central ... be able to access 24 hours a day, 7 ...
(Date:5/27/2015)... 27, 2015 The Case Management ... partnership to provide CMSA's Career and Knowledge Pathways ... seeks to strengthen the case/care management workforce by ... program. The mutually beneficial agreement provides Medix, a ... of talent in the healthcare, scientific and IT ...
(Date:5/27/2015)... View, CA (PRWEB) May 27, 2015 Coco ... Valley will be able to reach for Organic Coconut Water ... Coco Libre will be available at VIP areas, artist greenrooms, ... also be available at area hotels and on festival shuttle ... a partner this year,” said Noa Elan, Director of Strategic ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 ... of its SonarMD Platform, a first-of-its kind, ... and managing patients with chronic gastrointestinal disease. ... MD, MBA, the application allows physicians to ... through the ongoing use of electronic health ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 2Health News:AIS Newsletter Offers Coverage, Analysis of New CMS Strategy on Monitoring MA Provider Access 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Coco Libre Puts Organic Coconut Water on the Line-up at BottleRock Napa 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
(Date:5/27/2015)... REDWOOD CITY, Calif. , May 27, 2015  Genomic ... Brad Cole , Chief Operating Officer and Chief Financial Officer, ... New York City on Monday, June ... access the live and subsequently archived webcast of the presentation, ... site at http://investor.genomichealth.com .  Please connect to the web ...
(Date:5/27/2015)...  Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... that Ross Taylor , vice president of business ... chief financial officer effective August 1, 2015, will present ... June 4, 2015 at 10:00 a.m. ET. The conference ... New York City . About ...
(Date:5/27/2015)... DUBLIN, Ohio , May 27, 2015 /PRNewswire/ ... present a new series of health economic outcomes ... evaluating real-world treatment patterns when developing value-based reimbursement ... , vice president and chief medical officer of ... and pharmaceutical companies alike have known for more ...
Breaking Medicine Technology:Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference 2Genomic Health to Present at the Jefferies 2015 Global Healthcare Conference 3New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 2New Studies Reinforce Important Role Real-World Patient Data Can Play in Developing Value-based Reimbursement Strategies 3
Cached News: